GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Events / GHTM Session 2024: Plasmodium falciparum Artemisinin resistance in Africa – the beginning of the end or the end of the beginning for ACT?

GHTM Session 2024: Plasmodium falciparum Artemisinin resistance in Africa – the beginning of the end or the end of the beginning for ACT?

December 1, 2024

📅 Date: 13 December 2024
🕒 Time: 11:00-13:00
📍 Location: ZOOM & Sala Fraga de Azevedo | IHMT-NOVA

Plasmodium falciparum Artemisinin resistance in Africa – the beginning of the end or the end of the beginning for ACT?

For nearly two decades, artemisinin has been the cornerstone of Plasmodium falciparum malaria management globally. Despite the drug’s short half-life and rapid action initially making resistance seem unlikely, such resistance has emerged, though through a seemingly different mechanism.

Beginning in Southeast Asia, partial artemisinin resistance, as identified by the WHO, has also surfaced in Africa and continues to spread. The parasite strategy, based on a ring stage transient response aiming on decreasing the short-term artemisinin effects, represents a new concept in malaria probably applicable to new similarly acting drugs.

Join us for an insightful overview of the origins, development, and future outlook of artemisinin use in malaria treatment.

About José Pedro Gil

José Pedro Gil is an Associate Professor (Docent) in Molecular Pharmacology at the Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden. He earned his MSc from the University of Aberdeen, UK, in 1993, and his PhD from NOVA University in 2000. His research interests include drug resistance, particularly in the Plasmodium falciparum model, as well as pharmacogenetics and personalized medicine.

This session is hosted by Professor Jaime Nina and the Research Group IHC – Individual Health Care.

If you are not a GHTM member and would like to join the session, please contact us at ghtm-info@ihmt.unl.pt.

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to print (Opens in new window) Print

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

 

Loading Comments...
 

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok